Despite decades of effort, and tests that screen for five cancers in the U.S., cancer is projected to become the world’s leading killer in 2021.
That’s why GRAIL is pioneering Galleri™, a multi-cancer early detection test that can detect over 50 types of cancers — over 45 of which lack recommended screening today — with a low false positive rate, through a single blood draw.
We believe we have the potential to transform cancer care by reducing cancer deaths and decreasing healthcare costs by detecting more cancers earlier.
- Who We Are
- Our Approach
- Clinical Expertise
- Our Products